You are here: Industry Insights > PARP inhibitor

News List

Clovis Oncology Highlights Rubraca (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting firstwordpharma
May 20, 2021
Clovis Oncology, today announced that four abstracts featuring data will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually, June 4-8, 2021.
PARP inhibitors could exploit weaknesses in a range of cancers pharmatimes
April 26, 2021
PARP inhibitors – a type of drug most commonly used to treat ovarian and breast cancers – could offer a new way of targeting a range of cancers with a particular gene defect in the PBRM1 gene, according to researchers.
Oncology Venture Acquires PARP Inhibitor Program contractpharma
July 14, 2020
Now has full ownership of 2X-121, which is being developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19.
GSK books 19% sales growth for first quarter pharmatimes
May 05, 2020
GlaxoSmithKline has reported 19% growth in group sales to £9.1 billion for the first quarter.
Sales of Zai Lab’s PARP Inhibitor Reaching RMB46.90 Million in Macau, S.A.R., China and Hong Kong, S.A.R., China of China in 2019 PharmaSources/Caicai
March 31, 2020
According to the 2019 results and company progress released by Zai Lab on Mar. 19, the total sales revenue of niraparib (trade name: Zejula) reached USD6.60 million (around RMB46.90 million) in Hong Kong, S.A.R., China and Macau, S.A.R., China Region of C
GSK enters PARP space with TESARO acquisition pharmaphorum
December 05, 2018
GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its PARP inhibitor Zejula (niraparib).....
EU reviews first PARP inhibitor for breast cancer pharmatimes
July 18, 2018
MSD and AstraZeneca’s Lynparza will be the first PARP inhibitor to be reviewed in Europe for the treatment of breast cancer, after the European Medicines Agency validated the drug’s marketing application in this setting.